Third Harmonic Bio, Inc. (THRD)
NASDAQ: THRD · Real-Time Price · USD
11.68
+0.06 (0.52%)
Nov 21, 2024, 12:09 PM EST - Market open
Company Description
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions.
The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019.
Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Third Harmonic Bio, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Natalie Holles |
Contact Details
Address: 1700 Montgomery Street, Suite 210 San Francisco, California 94111 United States | |
| Phone | (209) 727-2457 |
| Website | thirdharmonicbio.com |
Stock Details
| Ticker Symbol | THRD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001923840 |
| CUSIP Number | 88427A107 |
| ISIN Number | US88427A1079 |
| Employer ID | 83-4553503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Natalie C. Holles | Chief Executive Officer and Director |
| Julie Person | Chief Administrative Officer |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Christopher Murphy | Chief Financial and Business Officer |
| Dr. Christopher J. Dinsmore Ph.D. | Chief Scientific Officer |
| Steven P. Sweeney | Senior Vice President of Development Operations |
| Dennis Dean Ph.D. | Chief Non-Clinical Development Officer |
| Jennifer Dittman | Chief Development Operations Officer |
| Ommer Chohan | Treasurer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 28, 2024 | 144 | Filing |
| Sep 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 19, 2024 | 144 | Filing |